Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis

Efficacy and Safety of Ibrutinib in Central Nervous System Lymphoma: A PRISMA-Compliant Single-Arm Meta-Analysis

BackgroundCentral nervous system lymphoma (CNSL) is an aggressive lymphoma. Studies investigating primary CNSL determined that the Bruton tyrosine kinase (BTK) played an important role in pathogenesis. Ibrutinib, an oral BTK inhibitor, is a new treatment strategy for CNSL. The purpose of this meta-a...

Full description

Bibliographic Details
Main Authors: Liwei Lv, Xuefei Sun, Yuchen Wu, Qu Cui, Yuedan Chen, Yuanbo Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
central nervous system lymphoma
ibrutinib
meta-analysis
single-arm
refractory
relapsed
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.707285/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.707285/full

Similar Items